Slide 1: Wockhardt Limited Investor Presentation
Wockhardt Limited Investor Presentation By Dr. Murtaza Khorakiwala Managing Director Aug 2013
Slide 2: Safe Harbor Statement
Safe Harbor Statement • Except for historical information contained herein, statements in this communication, which include words or phrases such as “will”, “aim”, “will likely result”, “would”, “believe”, “may”, “expect”, “will continue”, “anticipate”, “estimate”, “intend”, “plan”, “contemplate”, “
Slide 3: Introduction to Wockhardt
Introduction to Wockhardt Key Business Dynamics
Slide 4: Wockhardt Today
Wockhardt Today UK, Ireland, France, Switz. USA Direct Operations in India, USA Mexico India and Europe 8600 Associates employed in 21 countries Wockhardt Direct ROW operations operations Investor Presentation Aug 2013 4
Slide 5: Wockhardt Today
Wockhardt Today UK Ireland 9 sites Chicago in India 12 Baddi Manufacturing Locations globally Ankleshwar Daman (2 Plants) Aurangabad (5 Plants) Formulations APIs Investor Presentation Aug 2013 5
Slide 6: Wockhardt Today R&D Centers
Wockhardt Today 3 R&D Centers worldwide USA / UK & India Investor Presentation Aug 2013 6
Slide 7: Recent Events
Recent Events TWOCKHARDT
Slide 8: Recent Events: US FDA Actions
Recent Events 1. US FDA Actions Pursuant to Import Alert issued in May - 2013 FDA issued a Warning Letter in July for the Waluj Facility. This facility has one oral solid unit and two injectable units. Observations include - Need to increase laboratory controls Enhancement of training prog
Slide 9: Recent Events: US FDA Measures by Wockhardt
Recent Events 2. US FDA – Measures by Wockhardt Appointed US based M/s. Lachman GMP Consultant INC USA , to conduct a detailed review of our site and oversee implementation of Action Plan to meet FDA Requirements . Wockhardt has initiated several preventive and corrective measures including stre
Slide 10: Recent Events: UK MHRA Actions
Recent Events 3. UK MHRA Actions Pertains to our same WALUJ FACILITY under USFDA alert. On July 10, 2013 UK MHRA initiated a PRECAUTIONARY RECALL of 16 product lines to UK Market. These products have been tested on importation in UK and certified by a Qualified Professional before releasing to
Slide 11: Recent Events: Inspection Status Update
Recent Events 4. Inspection Status update – Chikalthana / Shendra USFDA and UK MHRA has conducted inspections at Chikalthana, Shendra and Cephalosporin plants during the month of July 13 . Status Update plant wise is as under : Shendra Plant – Inspection completed by UK MHRA and there are no “
Slide 12: Recent Events: Update on Spasmoproxyvon
Recent Events 5. Update on Spasmoproxyvon Government of India has suspended the manufacture and sale of Dextroproxyphene and formulation containing the same. Wockhardt received the communication of the same on 10th June 13 and immediately stopped manufacturing and selling the same. The Company
Slide 13: Q1FY14 Results
Q1FY14 Results TWOCKHARDT
Slide 14: Sales – Growth of 1% over Q1FY13
Sales – Growth of 1% over Q1FY13 Rs.crore Growth of 1% in Q1FY14 over Q1FY13 Investor Presentation Aug 2013 14
Slide 15: EBITDA – Declines by 5% over Q1FY13
EBITDA – Declines by 5% over Q1FY13 Rs.crore Declines by 5% in Q1FY14 over Q1FY13 Q1FY13 EBITDA adjusted for Rs.41 crores of R&D expenses for a like to like comparison Investor Presentation Aug 2013 15
Slide 16: Adj. PAT remains flat
Adj. PAT remains flat Rs.crore Remains flat Q1FY13 PAT adjusted for Rs.41 crores of R&D expenses for a like to like comparison Investor Presentation Aug 2013 16
Slide 17: Research – Increases to 7.7% of Sales
Research – Increases to 7.7% of Sales Investor Presentation Aug 2013 17
Slide 18: US Business: Growth trajectory continues
US Business: Growth trajectory continues • Growth of 11% (7% on $terms) over Q1FY13. • 4 ANDAs filed during the quarter • 50 ANDAs pending approval. Investor Presentation Aug 2013 18
Slide 19: EU Operations: Maintaining Balance
EU Operations: Maintaining Balance UK Operations • UK operation grows by 1% (1% in £ terms) in Q1FY14 • Slower growth more on account of Pinewood’s UK portfolio showing a negative growth. • No. 3 Generic company in UK • No. 2 in the hospital segment Ireland Operations • Ireland declines by 31% (35%
Slide 20: Emerging Markets – declines by 5%
Emerging Markets – declines by 5% • Emerging Markets declines by 5% for Q1FY14. • Indian Business grew at 3% over Q1FY13. • The growth was impacted due to uncertainty in trade due to NLEM issues, strike by retailers in Maharashtra and suspension of sale of Dextropropoxyphene • ROW operations decline
Slide 21: For investor updates and communication please visit www.wockhardt.com
For investor updates and communication please visit www.wockhardt.com For Information please contact Tushar Mistry Tel.: +91 22 26596210 tmistry@wockhardt.com Investor Presentation Aug 2013 21